Results You Can Trust
Embosphere Microspheres, the most clinically studiedround embolic, provide consistent and predictableresults or eective embolisation in the treatment o uterine broids, hypervascular tumours, arteriovenousmalormations and Benign Prostatic Hyperplasia (BPH).Embosphere Microspheres’ unique nonresorbable,resilient and cell-adhesive properties provide predictableoutcomes procedure ater procedure.Embosphere Microspheres are backed by decadeso research and are nonaggregating or predictabledistribution. With several size ranges and volumes tochoose rom, Embosphere Microspheres allow precisetargeted delivery.
Benign ProstaticHyperplasia (BPH)
Moderate to severe lower urinary tract symptoms(LUTS) due to benign prostatic hyperplasia (BPH) aictapproximately 50% o men aged 65 and older. At aroundage 50, the prostate gland—through which the urethrapasses—grows large enough to constrict the urethra. Forsome patients, quality o lie decreases due to requenturges to urinate and insucient voiding.Prostatic Artery Embolisation (PAE) is a less invasivetreatment option and selectively blocks blood fowto the prostate resulting in reduced prostate volumeand reduced urethral stricture. Clinical data hasdemonstrated that patients achieve durable symptomrelie while avoiding the complications and side eectsassociated with surgical or energy-based procedures andpharmacotherapy.
The hydrophilic surace and spherical shapeo Embosphere Microspheres preventaggregation in the catheter lumen and in thevasculature.
Because they are nonaggregating,Embosphere Microspheres distributepredictably ater embolisation.
Embosphere Microspheres are availablein size ranges and volumes that allow thephysician to select the right size spheres orthe targeted tissue.
40-120 µm100-300 µm300-500 µm500-700 µm700-900 µm900-1200 µm